Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2013

Koers Karlijn, Francken Anne Brecht, Haanen John B A G, Woerdeman Leonie A E, van der Hage Jos A

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Indoles
Lymph Nodes
Lymphatic Metastasis
Multimodal Imaging
Neoadjuvant Therapy
Positron-Emission Tomography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23569313
DOI: 10.1200/JCO.2012.45.3845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.PMID 23569313Read ↗

FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib for leptomeningeal melanomatosis.Semantic proximity Read ↗

Melanoma: Time for adjuvant vemurafenib?Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Systemic Therapy Options for Patients With Unresectable Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.